Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERTEX PHARMACEUTICALS

(VRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vertex Pharmaceuticals Up Over 7%, Best Performer in The S&P 500 and Nasdaq 100 So Far Today -- Data Talk

12/01/2021 | 11:22am EST

Vertex Pharmaceuticals Incorporated (VRTX) is currently at $200.44, up $13.50 or 7.22%

-- Would be highest close since Aug. 25, 2021, when it closed at $201.33

-- On pace for largest percent increase since April 2, 2020, when it rose 7.4%

-- Currently up two of the past three days

-- Down 15.19% year-to-date; on pace for worst year since 2016, when it fell 41.45%

-- Down 33.87% from its all-time closing high of $303.10 on July 20, 2020

-- Down 11.58% from 52 weeks ago (Dec. 2, 2020), when it closed at $226.70

-- Down 16.94% from its 52-week closing high of $241.31 on Jan. 25, 2021

-- Up 13.24% from its 52-week closing low of $177.01 on Oct. 5, 2021

-- Traded as high as $200.68; highest intraday level since Sept. 1, 2021, when it hit $202.55

-- Up 7.35% at today's intraday high; largest intraday percent increase since April 6, 2020, when it rose as much as 7.7%

-- Best performer in the S&P 500 today

-- Best performer in the Nasdaq 100 today

All data as of 10:59:52 AM ET

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

12-01-21 1122ET

Stocks mentioned in the article
ChangeLast1st jan.
VERTEX PHARMACEUTICALS 0.70% 229.68 Delayed Quote.4.59%
All news about VERTEX PHARMACEUTICALS
01/21NORTH AMERICAN MORNING BRIEFING : Dow Wobbles, -3-
DJ
01/20WALL STREET STOCK EXCHANGE : Nasdaq aims for rebound after entering correction territory
01/20ANALYST RECOMMENDATIONS : Activision Blizzard, AMD, Bumble, Etsy, Ford...
01/20BMO Capital Lifts Vertex Pharmaceuticals to Outperform From Market Perform, Price Targe..
MT
01/19SiteOne Therapeutics Announces Collaboration and License Agreement with Vertex Pharmace..
CI
01/18Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
BU
01/12Vertex Pharmaceuticals - European Commission Approves KAFTRIO (ivacaftor/tezacaftor/ele..
AQ
01/11Vertex's Cystic Fibrosis Combo Gets Extended EU Nod For Treating Children
MT
01/11Vertex Secures European Commission's Approval for Kaftrio With Ivacaftor as Treatment f..
MT
01/11European Commission Approves KAFTRIO« (ivacaftor/tezacaftor/elexacaftor) in Combination..
BU
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 7 502 M - -
Net income 2021 2 296 M - -
Net cash 2021 8 312 M - -
P/E ratio 2021 26,1x
Yield 2021 -
Capitalization 58 397 M 58 397 M -
EV / Sales 2021 6,68x
EV / Sales 2022 5,63x
Nbr of Employees 3 400
Free-Float -
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 229,68 $
Average target price 267,61 $
Spread / Average Target 16,5%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS4.59%57 990
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-1.60%64 971
WUXI APPTEC CO., LTD.-5.63%49 645
BIONTECH SE-42.79%35 624
BEIGENE, LTD.-7.19%25 835